Aquestive Therapeutics (AQST) Set to Announce Quarterly Earnings on Monday

Aquestive Therapeutics (NASDAQ:AQST) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, November 4th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Aquestive Therapeutics has set its FY 2024 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Tuesday, August 6th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.08. The business had revenue of $20.10 million for the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the previous year, the company posted ($0.10) EPS. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aquestive Therapeutics Stock Up 0.5 %

Aquestive Therapeutics stock opened at $5.52 on Friday. The stock has a 50-day simple moving average of $4.86 and a 200 day simple moving average of $3.80. The stock has a market capitalization of $502.65 million, a price-to-earnings ratio of -15.77 and a beta of 2.85. Aquestive Therapeutics has a 12-month low of $1.41 and a 12-month high of $6.23.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research report on Friday, October 25th. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, Leerink Partners boosted their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Aquestive Therapeutics has an average rating of “Buy” and a consensus price target of $8.83.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.